In July 2005, Declan Hamill joined Innovative Medicines Canada (formerly Canada’s Research-Based Pharmaceutical Companies – Rx&D), the national association representing the voice of Canada’s innovative pharmaceutical industry, as its General Counsel. Mr. Hamill was named Vice President of Legal Affairs and Intellectual Property (IP) Policy in February 2007, assuming leadership for IP issues in addition to his legal responsibilities and responsibilities for the industry’s Code of Ethical Practices. He is also the senior staff lead for the Ethics Committee, the Industry Practices Review Committee and Intellectual Property Subject Expert Group. Mr. Hamill is accountable to the President and to the Board of Directors.
In the capacity of Vice President, Legal, Mr. Hamill provides advice and counsel regarding legal, trade and compliance issues. He serves as the in-house resource to provide expertise and advice on recent jurisprudence and other legal and IP developments affecting the industry. Mr. Hamill liaises regularly with member company senior managers, corporate counsel, and compliance personnel.
In September 2016, Mr. Hamill assumed additional responsibility for the regulatory and policy functions at Innovative Medicines Canada.
Mr. Hamill has appeared before several Canadian government bodies and committees, including the House of Commons Industry, Science and Technology Committee, and the House of Commons Standing Committee on International Trade. Mr. Hamill has also been a speaker or panelist at a number of life sciences related events, including the Canadian Institute Pharma Patents conference, the Ontario Bar Association, the Centre for the Advancement of Health Innovations, the Canadian Association for Healthcare Reimbursement conference, and the BIO International conference.
Mr. Hamill is a graduate of National Program (LLB and BCL) of the McGill University Faculty of Law, and also holds degrees from York University and from
Day 1: Oct 6, 2020
Strategies for Managing Through the Adjusted Timeline and Transition to Implementation of the New Pricing Guidelines
Given the uncertainties created by the change in implementation date to the new pricing guidelines, navigating the marketplace will be challenging. Fine-tune your pricing strategy as the new guidelines gain clarity. Take away a road map to help your organization with:
- Strategies for product positioning and pricing
- Insights about determining factors on whether medicines will be classified as Category I or Category II
- Understanding what impact the current consultation process could have on the final guidelines and on your organization
Gain clarity on how to align your pricing strategies with the new PMPRB pricing guidelines as they emerge under the new implementation timeline
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020